肿瘤微环境在三阴性乳腺癌中的研究进展
The Progress of Tumour Microenvironment in Triple-Negative Breast Cancer
DOI: 10.12677/ACM.2023.1371641, PDF,   
作者: 刘亚茹：济宁医学院临床医学院，山东 济宁；马俊丽*：济宁医学院附属医院肿瘤科，山东 济宁
关键词: 三阴性乳腺癌；肿瘤微环境；免疫逃逸；转移；乳腺癌治疗；Triple Negative Breast Cancer； Tumor Microenvironment； Immune Escape； Transfers； Breast Cancer Therapy
摘要: 三阴性乳腺癌(triple negative breast cancer, TNBC)是乳腺癌中最具侵袭性的亚型，转移性和远处复发的发生率高，缺乏特异性靶点，易产生耐药性，这与它不同于其他亚型的独特肿瘤微环境(TME)密不可分。TME是肿瘤细胞赖以生存和发展的复杂环境，主要由肿瘤细胞、基质细胞及组织、微血管、以及各种趋化因子等构成。TME的存在提升了肿瘤细胞增殖、侵袭、转移及免疫逃逸能力，阻碍TNBC的抗肿瘤反应。肿瘤细胞与TME相辅相成，了解TME将有助于设计基于TNBC的靶向治疗。本文将针对于TME如何促进TNBC发生发展的最新研究进展进行综述。
Abstract: Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with a high incidence of metastasis and distant recurrence, a lack of specific targets and a tendency to develop drug resistance, which is inextricably linked to its unique tumour microenvironment (TME). The presence of TME enhances the proliferation, invasion, metastasis and immune escape of tumour cells and hinders the anti-tumour response of TNBC. Tumour cells and TME complement each other and understanding TME will help in the design of TNBC-based targeted therapies. This article re-views the latest research advances on how TME contributes to the development of TNBC.
文章引用：刘亚茹, 马俊丽. 肿瘤微环境在三阴性乳腺癌中的研究进展[J]. 临床医学进展, 2023, 13(7): 11713-11720. https://doi.org/10.12677/ACM.2023.1371641

参考文献

[1] Siegel, R.L., Miller, K.D., Goding Sauer, A., et al. (2020) Colorectal Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 145-164. [Google Scholar] [CrossRef] [PubMed]
[2] Wang, Q., Xu, M., Sun, Y., et al. (2019) Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study. Fron-tiers in Oncology, 9, Article 354. [Google Scholar] [CrossRef] [PubMed]
[3] Lotfinejad, P., Jafarabadi, M.A., Shadbad, M.A., et al. (2020) Prog-nostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study. Diagnostics, 10, Article 704. [Google Scholar] [CrossRef] [PubMed]
[4] Garrido-Castro, A.C., Lin, N.U. and Polyak, K. (2019) Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Dis-covery, 9, 176-198. [Google Scholar] [CrossRef] 
[5] Rey-Vargas, L., Sanabria-Salas, M.C., Fejerman, L. and Ser-rano-Gómez, S.J. (2019) Risk Factors for Triple-Negative Breast Cancer among Latina Women. Cancer Epidemiology, Biomarkers & Prevention, 28, 1771-1783. [Google Scholar] [CrossRef] 
[6] Burstein, M.D., Tsimelzon, A., Poage, G.M., et al. (2015) Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research, 21, 1688-1698. [Google Scholar] [CrossRef] 
[7] Jiang, Y.-Z., Ma, D., Suo, C., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440. [Google Scholar] [CrossRef] [PubMed]
[8] 刘娟, 郑唯强. AR和SKP2在三阴性乳腺癌中的表达及临床意义[J]. 医学研究杂志, 2019, 48(8): 20-26, 4.
[9] Liu, Y.-X., Zhang, K.-J. and Tang, L.-L. (2018) Clinical Significance of Androgen Receptor Expression in Triple Negative Breast Cancer—An Immunohistochemistry Study. Oncology Letters, 15, 10008-10016. [Google Scholar] [CrossRef] [PubMed]
[10] Lehmann, B.D., Bauer, J.A., Schafer, J.M., et al. (2014) PIK3CA Muta-tions in Androgen Receptor-Positive Triple Negative Breast Cancer Confer Sensitivity to the Combination of PI3K and Androgen Receptor Inhibitors. Breast Cancer Research, 16, Article No. 406. [Google Scholar] [CrossRef] [PubMed]
[11] Rodríguez-Bautista, R., Caro-Sánchez, C.H., Cabrera-Galeana, P., et al. (2021) Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior. Cancers, 13, Article No. 6256. [Google Scholar] [CrossRef] [PubMed]
[12] Tsang, J.Y.S. and Tse, G.M. (2020) Molecular Classification of Breast Cancer. Advances in Anatomic Pathology, 27, 27-35. [Google Scholar] [CrossRef] 
[13] Liedtke, C., Mazouni, C., Hess, K.R., et al. (2008) Response to Neoadjuvant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer. Journal of Clinical Oncology, 26, 1275-1281. [Google Scholar] [CrossRef] 
[14] Sharma, P. (2016) From the Guest Editor: Immune Checkpoint Therapy as a Weapon against Cancer. The Cancer Journal, 22, 67. [Google Scholar] [CrossRef] 
[15] Lu, P., Weaver, V.M. and Werb, Z. (2012) The Extracellular Matrix: A Dynamic Niche in Cancer Progression. Journal of Cell Biology, 196, 395-406. [Google Scholar] [CrossRef] [PubMed]
[16] Orimo, A., Gupta, P.B., Sgroi, D.C., et al. (2005) Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion. Cell, 121, 335-348. [Google Scholar] [CrossRef] [PubMed]
[17] Ge, Z. and Ding, S. (2020) The Crosstalk Between Tu-mor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy. Frontiers in Oncolo-gy, 10, Article 590941. [Google Scholar] [CrossRef] [PubMed]
[18] Wicha, M.S., Liu, S. and Dontu, G. (2006) Cancer Stem Cells: An Old Idea—A Paradigm Shift. Cancer Research, 66, 1883-1890. [Google Scholar] [CrossRef] 
[19] Dou, J. and Gu, N. (2010) Emerging Strategies for the Identification and Targeting of Cancer Stem Cells. Tumor Biology, 31, 243-253. [Google Scholar] [CrossRef] [PubMed]
[20] Murray, P.J. and Wynn, T.A. (2011) Obstacles and Opportunities for Understanding Macrophage Polarization. Journal of Leukocyte Biology, 89, 557-563. [Google Scholar] [CrossRef] [PubMed]
[21] Solinas, G., Germano, G., Mantovani, A. and Allavena, P. (2009) Tu-mor-Associated Macrophages (TAM) as Major Players of the Cancer-Related Inflammation. Journal of Leukocyte Biolo-gy, 86, 1065-1073. [Google Scholar] [CrossRef] [PubMed]
[22] Spranger, S. (2016) Mechanisms of Tumor Escape in the Context of the T-Cell-Inflamed and the Non-T-Cell-Inflamed Tumor Microenvironment. International Immunology, 28, 383-391. [Google Scholar] [CrossRef] [PubMed]
[23] Xiao, Y., Ma, D., Zhao, S., et al. (2019) Multi-Omics Profiling Re-veals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clinical Cancer Research, 25, 5002- 5014. [Google Scholar] [CrossRef] 
[24] Chen, M., Sharma, A., Lin, Y., et al. (2019) Insluin and Epithelial Growth Factor (EGF) Promote Programmed Death Ligand 1(PD-L1) Production and Transport in Colon Cancer Stem Cells. BMC Cancer, 19, Article No. 153. [Google Scholar] [CrossRef] [PubMed]
[25] Anders, C.K., Abramson, V., Tan, T. and Dent, R. (2016) The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. American Society of Clinical Oncology Educational Book, 36, 34-42. [Google Scholar] [CrossRef] 
[26] Chen, L. and Han, X. (2015) Anti-PD-1/PD-L1 Therapy of Human Cancer: Past, Present, and Future. Journal of Clinical Investigation, 125, 3384-3391. [Google Scholar] [CrossRef] 
[27] Xu, P., Xiong, W., Lin, Y., et al. (2021) Histone Deacetylase 2 Knockout Suppresses Immune Escape of Triple-Negative Breast Cancer Cells via Downregulating PD-L1 Expression. Cell Death & Disease, 12, Article No. 779. [Google Scholar] [CrossRef] [PubMed]
[28] Wu, B., Song, M., Dong, Q., et al. (2022) UBR5 Promotes Tumor Immune Evasion through Enhancing IFN-γ-Induced PDL1 Transcription in Triple Negative Breast Cancer. Theranostics, 12, 5086-5102. [Google Scholar] [CrossRef] [PubMed]
[29] Yamashita, N., Long, M., Fushimi, A., et al. (2021) MUC1-C Integrates Activation of the IFN-γ Pathway with Suppression of the Tumor Immune Microenvironment in Triple-Negative Breast Cancer. Journal for ImmunoTherapy of Cancer, 9, e002115. [Google Scholar] [CrossRef] [PubMed]
[30] Hao, Q. and Tang, H. (2018) Interferon-γ and Smac Mimetics Synergize to Induce Apoptosis of Lung Cancer Cells in a TNFΑ-Independent Manner. Cancer Cell International, 18, Article No. 84. [Google Scholar] [CrossRef] [PubMed]
[31] Chen, X. and Cubillos-Ruiz, J.R. (2021) Endoplasmic Reticulum Stress Signals in the Tumour and Its Microenvironment. Nature Reviews Cancer, 21, 71-88. [Google Scholar] [CrossRef] [PubMed]
[32] Yao, X., Tu, Y., Xu, Y., et al. (2020) Endoplasmic Reticulum Stress-Induced Exosomal miR-27a-3p Promotes Immune Escape in Breast Cancer via Regulating PD-L1 Expression in Macrophages. Journal of Cellular and Molecular Medicine, 24, 9560-9573. [Google Scholar] [CrossRef] [PubMed]
[33] Chen, D. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. [Google Scholar] [CrossRef] [PubMed]
[34] Bagati, A., Kumar, S., Jiang, P., et al. (2021) Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. Cancer Cell, 39, 54-67. [Google Scholar] [CrossRef] [PubMed]
[35] Wu, Y., Yi, Z., Li, J., et al. (2022) FGFR Blockade Boosts T Cell Infiltration into Triple-Negative Breast Cancer by Regulating Cancer-Associated Fibroblasts. Theranostics, 12, 4564-4580. [Google Scholar] [CrossRef] [PubMed]
[36] Engel, J.B., Honig, A., Kapp, M., et al. (2014) Mechanisms of Tumor Immune Escape in Triple-Negative Breast Cancers (TNBC) with and without Mutated BRCA 1. Archives of Gynecology and Obstetrics, 289, 141-147. [Google Scholar] [CrossRef] [PubMed]
[37] Yamaguchi, T., Wing, J.B. and Sakaguchi, S. (2011) Two Modes of Immune Suppression by Foxp3+ Regulatory T Cells under Inflammatory or Non-Inflammatory Conditions. Seminars in Immunology, 23, 424-430. [Google Scholar] [CrossRef] [PubMed]
[38] Zou, W. (2005) Immunosuppressive Networks in the Tumour En-vironment and Their Therapeutic Relevance. Nature Reviews Cancer, 5, 263-274. [Google Scholar] [CrossRef] [PubMed]
[39] Quail, D.F. and Joyce, J.A. (2013) Microenvironmental Regulation of Tumor Progression and Metastasis. Nature Medicine, 19, 1423-1437. [Google Scholar] [CrossRef] [PubMed]
[40] Joyce, J.A. and Pollard, J.W. (2009) Microenvironmental Regulation of Metastasis. Nature Reviews Cancer, 9, 239-252. [Google Scholar] [CrossRef] [PubMed]
[41] Dvorak, K.M., Pettee, K.M., Rubinic-Minotti, K., et al. (2018) Carcinoma Associated Fibroblasts (CAFs) Promote Breast Cancer Motility by Suppressing Mammalian Diaphanous-Related For-min-2 (mDia2). PLOS ONE, 13, e0195278. [Google Scholar] [CrossRef] [PubMed]
[42] Picarda, E., Ohaegbulam, K.C. and Zang, X. (2016) Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clinical Cancer Research, 22, 3425-3431. [Google Scholar] [CrossRef] 
[43] Cheng, N., Bei, Y., Song, Y., et al. (2021) B7-H3 Aug-ments the Pro-Angiogenic Function of Tumor-Associated Macrophages and Acts as a Novel Adjuvant Target for Tri-ple-Negative Breast Cancer Therapy. Biochemical Pharmacology, 183, Article ID: 114298. [Google Scholar] [CrossRef] [PubMed]
[44] Chaturvedi, P., Gilkes, D.M., Takano, N., et al. (2014) Hypox-ia-Inducible Factor-Dependent Signaling between Triple- Negative Breast Cancer Cells and Mesenchymal Stem Cells Promotes Macrophage Recruitment. Proceedings of the National Academy of Sciences of the United States of America, 111, E2120-E2129. [Google Scholar] [CrossRef] [PubMed]
[45] Li, X., Chen, M., Lu, W., et al. (2021) Targeting FAPα-Expressing Tumor-Associated Mesenchymal Stromal Cells Inhibits Triple-Negative Breast Cancer Pulmonary Metastasis. Cancer Letters, 503, 32-42. [Google Scholar] [CrossRef] [PubMed]
[46] Tsai, Y.-F., Huang, C.-C., Lin, Y.-S., et al. (2021) Interleukin 17A Promotes Cell Migration, Enhances Anoikis Resistance, and Creates a Microenvironment Suitable for Triple Nega-tive Breast Cancer Tumor Metastasis. Cancer Immunology, Immunotherapy, 70, 2339-2351. [Google Scholar] [CrossRef] [PubMed]
[47] Wang, R., Lou, X., Feng, G., et al. (2019) IL-17A-Stimulated Endothelial Fatty Acid β-Oxidation Promotes Tumor Angiogenesis. Life Sciences, 229, 46-56. [Google Scholar] [CrossRef] [PubMed]
[48] Masuda, H., Baggerly, K.A., Wang, Y., et al. (2013) Differential Response to Neoadjuvant Chemotherapy among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clinical Cancer Research, 19, 5533-5540. [Google Scholar] [CrossRef] 
[49] Sun, X., Wang, M., Wang, M., et al. (2020) Metabolic Re-programming in Triple-Negative Breast Cancer. Frontiers in Oncology, 10, Article 428. [Google Scholar] [CrossRef] [PubMed]
[50] Tsai, T.-H., Yang, C.-C., Kou, T.-C., et al. (2021) Overexpression of GLUT3 Promotes Metastasis of Triple-Negative Breast Cancer by Modulating the Inflammatory Tumor Microenviron-ment. Journal of Cellular Physiology, 236, 4669-4680. [Google Scholar] [CrossRef] [PubMed]

为你推荐